Chediak-Higashi syndrome (CHS) represents a rare autosomal recessive disorder that can affect multiple systems in the body. People with CHS often have lighter skin and hair than others in their family, frequent infections, and a tendency to bruise or bleed easily. The condition stems from mutations in the LYST gene, which encodes the lysosomal trafficking regulator protein. This large 429-kilodalton cytoplasmic protein orchestrates complex membrane trafficking events essential for cellular homeostasis.¹

The disease can appear in infancy or childhood, and in more severe cases, it leads to a dangerous inflammatory episode called the accelerated phase.

A quick genetics refresher

• Genes are instructions stored in DNA that tell cells how to make proteins
• Mutations are changes in these instructions that can alter or stop the protein’s function
• Autosomal recessive means a person must inherit a non-working gene copy from both parents to develop the disease. Parents who have only one non-working copy are carriers — they usually have no symptoms

Because CHS is autosomal recessive, it is rare and usually appears when both parents carry the same defective LYST gene.

Genetic foundation and protein structure

The LYST gene spans 53 exons across approximately 222 kilobases of genomic DNA on chromosome 1q42.3. Current research identifies 147 distinct disease-causing variants, with frameshift mutations comprising 41% of cases, nonsense variants 30%, and missense mutations 16%. This distribution suggests that protein-truncating variants cause more severe disease phenotypes compared to missense mutations that preserve partial protein function.¹

The LYST protein contains several critical functional domains that work in coordination. The BEACH (Beige and Chediak-Higashi) domain represents the most conserved region and likely mediates protein-protein interactions essential for membrane trafficking. The pleckstrin homology domain facilitates membrane targeting and cellular localisation. ARM/HEAT repeat domains contribute to protein scaffolding functions, while WD40 domains create platforms for multi-protein complex assembly.^2,3

Real-life impact of CHS

In everyday life, CHS may cause:

• Frequent bacterial infections that need strong antibiotics
• Sensitivity to sunlight and vision problems due to albinism
• Easy bruising and prolonged bleeding from minor cuts
• Fatigue and difficulty recovering from illness
• Social challenges are linked to visible symptoms, such as very light skin or hair

Children with the syndrome might miss school often due to illness. Families may need to schedule frequent hospital visits for treatment or monitoring.

Primary mechanism: Autophagic lysosome reformation dysfunction

Recent investigations reveal that LYST deficiency primarily disrupts autophagic lysosome reformation, a process crucial for maintaining lysosomal homeostasis. During normal autophagy, autolysosomes form tubular extensions from which nascent lysosomes undergo scission to restore the cellular lysosome pool. LYST-deficient neurons exhibit hyperelongated autolysosome tubules with failed scission events, resulting in lysosome depletion and formation of enlarged lysosomal structures.⁴

This dysfunction manifests as a marked reduction in small lysosomes, coupled with an increase in the number of abnormally large lysosomes. The hyperelongated tubules contain swollen structures representing nascent protolysosomes that remain attached rather than being released as functional lysosomes. Consequently, cells experience chronic lysosome shortage despite maintaining normal degradative capacity within existing organelles.⁴

Membrane trafficking defects

LYST mutations disrupt multiple aspects of membrane trafficking beyond lysosome reformation. The protein functions as a scaffolding regulator that coordinates vesicle fusion and fission events throughout the endolysosomal system. Loss of LYST function impairs the formation of late endosomal compartments positive for Rab7, which serve as critical sites for specific signalling pathways.⁵

Natural killer cells from patients demonstrate severely reduced cytotoxicity due to defective lytic granule exocytosis. Mutations affecting the ARM/HEAT domains produce enlarged granules that polarise to immunological synapses but fail to fuse with plasma membranes. Conversely, BEACH domain mutations result in normal-sized granules with impaired polarisation but preserved exocytic capability once they reach target sites.³

How CHS differs from other genetic diseases

While many genetic diseases affect a single organ, CHS impacts several systems because lysosomes operate in almost every cell type. For example:

• Cystic fibrosis mainly affects the lungs and digestive tract by altering mucus consistency
• Sickle cell anaemia primarily affects red blood cells
• CHS impairs immune cells, pigment-producing cells, platelets, and nerve cells — leading to a wide variety of symptoms

Cellular consequences across multiple systems

The trafficking defects produce distinct pathological changes in different cell types. Neutrophils develop enlarged azurophilic granules with impaired bactericidal activity due to defective phagolysosomal fusion. This contributes to the recurrent bacterial infections characteristic of the syndrome. Melanocytes form giant melanosomes that prevent even pigment distribution, causing the partial oculocutaneous albinism observed in patients.⁷

Platelets exhibit absent or reduced dense granules, leading to impaired aggregation and the bleeding diathesis seen clinically. The immunodeficiency involves multiple mechanisms, including defective natural killer cell cytotoxicity, impaired neutrophil chemotaxis, and disrupted antigen presentation due to abnormal granule exocytosis.⁸

Genotype-Phenotype Correlations

Clinical severity correlates strongly with mutation type and location. Patients harbouring at least one missense or in-frame variant generally present with milder disease courses, while those with two protein-truncating variants develop more severe manifestations. Missense mutations concentrated in the BEACH domain often preserve some protein function, potentially explaining the attenuated phenotypes.⁹

The accelerated phase, characterised by hemophagocytic lymphohistiocytosis, develops in 50-85% of patients and represents the most life-threatening complication. This hyperinflammatory state typically occurs in childhood and proves fatal without hematopoietic stem cell transplantation. Patients with missense mutations show reduced risk for developing this accelerated phase.⁶

Therapeutic implications and current management

Hematopoietic stem cell transplantation remains the definitive treatment for the hematologic and immunologic manifestations of Chediak-Higashi syndrome. Transplantation performed before the development of the accelerated phase achieves better outcomes, with reduced-intensity conditioning regimens showing improved survival rates compared to traditional myeloablative approaches. However, transplantation does not prevent progressive neurologic deterioration, which affects nearly all patients regardless of treatment status.⁶

Recent research into autophagic lysosome reformation dysfunction opens potential therapeutic avenues. Understanding that LYST regulates membrane fission events suggests that compounds enhancing lysosomal biogenesis or improving membrane dynamics might provide clinical benefit. Gene therapy approaches targeting the underlying genetic defect represent another promising direction, though the large size of the LYST gene presents technical challenges.⁶

Research directions and molecular insights

Current investigations focus on elucidating the precise molecular mechanisms by which LYST coordinates membrane trafficking events. The protein appears to function through recruitment to lysosomal membranes, where it facilitates scission of autolysosome tubules. This occurs through interactions with other membrane-associated proteins, though the complete network of LYST binding partners remains incompletely characterised.⁴

Studies using patient-derived induced pluripotent stem cells provide valuable models for investigating disease mechanisms and testing potential therapies. These cellular models recapitulate the lysosomal abnormalities observed in patients and offer platforms for drug screening and mechanistic studies. Additionally, they enable investigation of tissue-specific effects, particularly in neurons, where lysosomal dysfunction contributes to the progressive neurodegeneration.⁴

Why rare diseases matter?

Although CHS affects very few people worldwide, studying it helps scientists understand lysosome function — knowledge that can feed into treatments for more common conditions such as neurodegenerative diseases.

Rare disease research also highlights the need for:

• Better genetic screening
• Accessible specialised care
• Support networks for patients and their families

Summary

LYST gene mutations cause Chediak-Higashi syndrome through the disruption of fundamental membrane trafficking processes, particularly autophagic lysosome reformation. The resulting cellular dysfunction manifests across multiple organ systems, producing the characteristic clinical features of immunodeficiency, bleeding tendency, hypopigmentation, and neurologic abnormalities. Understanding these mechanisms provides insights into basic cellular biology while informing the development of targeted therapeutic approaches. The complexity of LYST function underscores the intricate nature of membrane trafficking regulation and highlights how single-gene defects can produce multisystem disease through disruption of fundamental cellular processes.